Achievable logoAchievable logo
PTCE
Sign in
Sign up
Purchase
Textbook
Practice exams
Support
How it works
Exam catalog
Mountain with a flag at the peak
Textbook
Introduction
1. Medications
2. Patient safety and quality assurance
3. Order entry and processing
4. Federal requirements
Wrapping up
Achievable logoAchievable logo
1.4.8.4 Treatment of ADHD
Achievable PTCE
1. Medications
1.4. Medications by organ system
1.4.8. Drugs of the nervous system
Our PTCE course is now in "early access" - get 50% off for a limited time.

Treatment of ADHD

2 min read
Font
Discuss
Share
Feedback

Drugs used in the treatment of ADHD

ADHD (attention deficit hyperactivity disorder) is characterized by inattention, hyperactivity, and impulsivity that often begins in childhood. Along with behavioral therapy, medications can help manage ADHD symptoms. The main medication groups are stimulants and non-stimulants.

Stimulants: These drugs increase arousal in the prefrontal cortex. Common stimulants include methylphenidate (Ritalin, Methylin, Concerta, Focalin) and amphetamines (Adderall, Evekeo, Dexedrine, Vyvanse).

  • Vyvanse contains lisdexamfetamine.
  • Adderall contains a combination of amphetamine and dextroamphetamine.

Mechanism: Stimulants increase dopamine and norepinephrine concentrations in the synaptic cleft in the brain.

Formulations: Methylphenidate is available in multiple forms, including tablets, solutions, chewables, suspension, extended-release tablets, and orally disintegrating tablets.

Adverse effects: Stimulants can cause decreased appetite, nausea, weight loss, sleep disturbances, headache, tics, increased heart rate and blood pressure, irritability, seizures, psychosis, euphoria, mania, and depression.

Safety and prescribing notes:

  • Stimulants have a high abuse potential and are classified as DEA Schedule II drugs.
  • Stimulants are contraindicated with MAOIs and in glaucoma.
  • Use caution in patients with cardiovascular disease, hyperthyroidism, and hypertension.
Ritalin
Ritalin

Non-stimulants: These drugs include atomoxetine (Strattera), clonidine (Catapres, Onyda), and guanfacine (Intuniv).

  • Atomoxetine is a norepinephrine reuptake inhibitor. It increases norepinephrine and dopamine concentrations in the prefrontal cortex.
  • Clonidine and guanfacine are alpha 2 agonists.

Adverse effects: Non-stimulants can cause suicidal tendency (Strattera), decreased appetite, nausea, vomiting, diarrhea, fatigue, mood swings, dizziness, insomnia, liver damage, and prolongation of the QT interval.

Abuse potential: Non-stimulants do not have abuse potential.

Sign up for free to take 6 quiz questions on this topic

All rights reserved ©2016 - 2026 Achievable, Inc.